Fulgent Genetics (NASDAQ:FLGT) Updates FY 2025 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of -0.650–0.650 for the period, compared to the consensus earnings per share estimate of -0.460. The company issued revenue guidance of $310.0 million-$310.0 million, compared to the consensus revenue estimate of $324.2 million. Fulgent Genetics also updated its FY25 guidance to $(0.65) EPS.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Piper Sandler cut their target price on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th.

Fulgent Genetics Stock Performance

FLGT opened at $15.69 on Friday. Fulgent Genetics has a one year low of $15.38 and a one year high of $25.11. The stock’s fifty day moving average is $17.37 and its 200-day moving average is $19.55. The company has a market capitalization of $479.91 million, a PE ratio of -2.84 and a beta of 1.39.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.